GenMark Diagnostics Stock News

GenMark Diagnostics, Inc (NASDAQ:GNMK) has received a consensus recommendation of “Buy” from the seven research firms that are covering the company, Marketbeat.com reports. Three research analysts

Stocks Analysis by Harry Boxer covering: Alcoa Corp, Occidental Petroleum Corporation, Apache Corporation, Valero Energy Corporation. Read Harry Boxer's latest article on Investing.com

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu

GenMark Diagnostics, Inc (NASDAQ:GNMK) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 2,890,000 shares, an increase of 19.4% fro

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) AstraZeneca plc (NYSE:...

GenMark Diagnostics (NASDAQ:GNMK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports. According to Zac

GenMark Diagnostics (GNMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GenMark Diagnostics (GNMK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nuveen Asset Management LLC raised its holdings in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 26.0% during the fourth quarter, according to the company in its most recent 13F filing with the

GenMark Diagnostics (NASDAQ:GNMK) is scheduled to release its earnings data after the market closes on Monday, May 4th. Analysts expect GenMark Diagnostics to post earnings of ($0.16) per share for th

As the market moves with COVID epidemiological data many stocks took a hit on questionable or incomplete news from the WHO on a clinical study in China on Remdesivir; Gilead Sciences stock took a hit

GenMark Diagnostics (NASDAQ:GNMK) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Saturday, BidAskClub reports. Other equities

Bank of New York Mellon Corp grew its stake in shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) by 2.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional inves